Evolent Health, Inc. (EVH)
NYSE: EVH · Real-Time Price · USD
4.200
-0.110 (-2.55%)
Nov 26, 2025, 4:00 PM EST - Market closed
Evolent Health Revenue
Evolent Health had revenue of $479.53M in the quarter ending September 30, 2025, a decrease of -22.83%. This brings the company's revenue in the last twelve months to $2.05B, down -16.65% year-over-year. In the year 2024, Evolent Health had annual revenue of $2.55B with 30.09% growth.
Revenue (ttm)
$2.05B
Revenue Growth
-16.65%
P/S Ratio
0.24
Revenue / Employee
$456,456
Employees
4,500
Market Cap
468.72M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.55B | 590.85M | 30.09% |
| Dec 31, 2023 | 1.96B | 611.88M | 45.26% |
| Dec 31, 2022 | 1.35B | 444.06M | 48.91% |
| Dec 31, 2021 | 907.96M | -16.68M | -1.80% |
| Dec 31, 2020 | 924.64M | 237.52M | 34.57% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
EVH News
- 15 days ago - Evolent Health, Inc. (EVH) Presents at UBS Global Healthcare Conference 2025 Transcript - Seeking Alpha
- 19 days ago - Evolent Health, Inc. (EVH) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 20 days ago - Evolent and American Oncology Network unveil innovative model seeking to improve cancer care while eliminating prior authorization burden - PRNewsWire
- 20 days ago - Evolent Announces Third Quarter 2025 Results - PRNewsWire
- 7 weeks ago - Evolent To Release Third Quarter 2025 Financial Results on Thursday, November 6, 2025 - PRNewsWire
- 2 months ago - Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners - PRNewsWire
- 3 months ago - Evolent's Soft Q2 Results: Why I'm Holding Anyway - Seeking Alpha
- 3 months ago - Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock - PRNewsWire